RE:RE:Antibe Director to Leave Position (As CEO of MaRS) Ya - as a serial entrepreneur, Yung Wu likely isn't the guy to run ATE.
Right now we have a Lawyer and in the future it will likely have a Drug guy - or - sold and someone else will decide how it gets folded in.
Right now - I'd be surprised if ATE would make any changes midstream.
All eyes on PK/PD ... then P2-Acute ... then readout. During that time, they are likely planning AME/P3-chronic or P2-Chronic.
All of this depends on PK/PD first - then on DILIsym (both acute and chronic) and then the trial plans going forward. Lots to be determined in 2023. A very busy year.
Likely won't complicate with any other changes - just my opinion.